U-Neuron Biomedical's current cash is $450M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), 6973.TWO shows a current cash of $450M. That compares with $180M in the prior-year period — up 150.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 6973.TWO's current cash is now $450M (was $180M) — a 150.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether U-Neuron Biomedical is outperforming or lagging.
Tracking 6973.TWO's current cash over time shows whether U-Neuron Biomedical is scaling, shrinking, or reshaping that part of the business. The current reading is $450M That compares with $180M in the prior-year period — up 150.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has U-Neuron Biomedical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $450M) with ownership activity and broader fundamentals.
U-Neuron Biomedical's current cash is $450M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.